Korea's Celltrion Sells 10 Percent Of Its Shares To Singapore's Temasek To Fund Biosimilar Development
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korean biotech Celltrion plans on speeding up development of its biosimilars by selling a 10 percent stake in the company to Singapore's Ion Investments B.V., a wholly-owned subsidiary of Temasek Holdings
You may also be interested in...
Celltrion CEO Cites Pfizer, J&J and Sanofi As Potential Buyers For Biosimilars Business
Although Korea’s Celltrion is not in takeover talks yet, CEO Seo Jung-jin named potential buyers after announcing he would sell his stake in the company he founded. Celltrion is expecting approval shortly in Europe for a biosimilar of J&J’s Remicade.
Singapore's Ion Investments Buys Another 10% Stake In Korea's Celltrion In Anticipation of 2012 Biosimilars Launch
SEOUL - Celltrion, Inc. said Sept. 1 that Singapore's Ion Investments B.V., a wholly-owned subsidiary of Temasek Holdings Pte. Ltd., purchased 10% of the outstanding shares of Celltrion Healthcare Co., Celltrion's global distribution and marketing arm, increasing the investor's share in the Korean company
Singapore's Ion Investments Buys Another 10% Stake In Korea's Celltrion In Anticipation of 2012 Biosimilars Launch
SEOUL - Celltrion, Inc. said Sept. 1 that Singapore's Ion Investments B.V., a wholly-owned subsidiary of Temasek Holdings Pte. Ltd., purchased 10% of the outstanding shares of Celltrion Healthcare Co., Celltrion's global distribution and marketing arm, increasing the investor's share in the Korean company